CHICAGO (MedPage Today) -- Survival in advanced non-small cell lung cancer (NSCLC) failed to improve with pemetrexed (Alimta) versus paclitaxel in combination chemotherapy, results of a large randomized trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment